Skip to main content
Analysis:
Analysis
27 May 2022
5 minute read

Deloitte Dialogue powered by J&J

Sustainability of the pharmaceutical industry under the NHI

Sustainability of the pharmaceutical industry under the NHI
526 KB PDF

Under the NHI, governments’ focus is to maintain a cost-conscious drug procurement policy, so the primary focus will be on the essential medicines list, the price of medication, devices and services. In this scenario, what is the future for innovative pharmaceutical companies in South Africa and how does the industry support the NHI to enable more patients to have access to affordable medication, but also ensure the sustainability of the SA pharma sector?

On Friday, 6th May 2022, Deloitte Africa, in partnership with Johnson & Johnson, joined by representatives from Government, hosted a roundtable discussion to address the future of the industry. Deloitte Africa’s Life Sciences and Health Care Industry Leader/Chief Sustainability Officer, Ashleigh Theophanides, facilitated the conversation which comprised of the following guest panel:

  • Dr Mark Blecher: Chief Director, Health and Social Development, National Treasury
  • Rashmee Ragaven: Senior Manager, Invest SA, The Department of Trade, Industry and Competition (DTIC)
  • Aluwani Museisi: Senior Director, Government Affairs & Policy, Sub-Saharan Africa, Johnson & Johnson

Did you find this useful?

Yes
No

Thanks for your feedback

If you would like to help improve Deloitte.com further, please complete a 3-minute survey

Key contact

Ashleigh Theophanides

Chief Sustainability Officer
+27 11 209 8112

Recommendations

Deloitte Digital Dialogue powered by J&J

Covid-19 has amplified the need for an improved healthcare system in order to better service our people. There needs to be collaboration between pharmaceutical companies and government in using innovation to minimise the high-cost implications associated with implementing a National Health Insurance programme.
Analysis
5 minute read

2021 Global health care sector outlook

Rising health care costs. Changing patient demographics. Evolving consumer expectations. New market entrants. Complex health and technology ecosystems.
Analysis
15 minute read

2021 global life sciences outlook

Navigating the pandemic has been an all-encompassing, once-in-a-lifetime challenge. Globally, life sciences companies responded with leadership and are emerging stronger. How will life sciences companies continue to respond and what areas can they build resiliency going forward?
Analysis
10 minute read

Achieving equity within Life Sciences & Health Care Sectors Webinar Life Sceince & Healthcare Deloitte South Africa

Health equity is a crucial concern among life sciences and health care organisations. Business leaders in the sector recognise that their organisations must close gaps in health disparities by focusing in part on diversity, equity and inclusion (DE&I) within their own workforce.
Analysis
2 minute read